Saphetor

Executive Summary

Saphetor is a Swiss bioinformatics company specializing in genomic variant interpretation through its VarSome platform. Founded in 2014 and headquartered in Lausanne, the company provides a suite of tools for next-generation sequencing (NGS) data analysis, ranging from a free community-driven database (VarSome.com) to premium (VarSome Premium) and clinical-grade (VarSome Clinical) versions. The platform aggregates data from multiple sources, offering researchers and clinicians a centralized solution for variant classification, filtering, and reporting. By enabling efficient and standardized interpretation of genetic variants, Saphetor addresses the growing demand for scalable genomics tools in diagnostic and research settings. The company operates in the rapidly expanding genomics market, driven by the increasing adoption of NGS in personalized medicine and rare disease diagnostics. While Saphetor has established a strong user base through its free tier, its monetization relies on subscriptions from institutional customers seeking advanced features, regulatory compliance, and integration capabilities. The competitive landscape includes players like Illumina's BaseSpace, Qiagen's Ingenuity, and other variant interpretation software. Saphetor's differentiation lies in its community-driven curation and clinical-grade offerings. Looking ahead, the company’s growth will depend on expanding its customer base, securing regulatory certifications (e.g., CE-IVD marking under IVDR), and forming partnerships with diagnostic labs and pharmaceutical companies.

Upcoming Catalysts (preview)

• Q4 2026CE-IVD certification for VarSome Clinical under IVDR70% success
• Q2 2026Strategic partnership with a major diagnostic laboratory50% success
• Q1 2027Series B funding round to scale commercial operations60% success